Eliem Therapeutics SG&A Expense (Quarterly) Trends

Eliem Therapeutics Inc (ELYM)

10.16 +1.76 (+21.04%) USD | NASDAQ | May 03, 16:00

10.14 -0.02 (-0.15%) After-Hours: 20:00

SG&A Expense (Quarterly) Chart

Historical SG&A Expense (Quarterly) Data

View and export this data back to 2020. Upgrade now.

Date	Value
December 31, 2023	1.995M
September 30, 2023	2.125M
June 30, 2023	3.026M
March 31, 2023	17.72M
December 31, 2022	4.627M
September 30, 2022	4.49M
June 30, 2022	4.932M
March 31, 2022	4.872M

Date	Value
December 31, 2021	3.824M
September 30, 2021	3.394M
June 30, 2021	2.914M
March 31, 2021	2.218M
December 31, 2020	1.537M
September 30, 2020	0.312M
June 30, 2020	0.248M
March 31, 2020	0.328M

SG&A Expense Definition

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (Quarterly) Range, Past 5 Years

0.248M

Minimum

Jun 2020

17.72M

Maximum

Mar 2023

3.66M

Average

2.97M

Median

SG&A Expense (Quarterly) Benchmarks